Bortezomib/dexamethasone ( DrugBank: Bortezomib, Dexamethasone )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 283 | Acquired pure red cell aplasia | 1 |
283. Acquired pure red cell aplasia
Clinical trials : 19 / Drugs : 36 - (DrugBank : 23) / Drug target genes : 20 - Drug target pathways : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04423367 (ClinicalTrials.gov) | September 13, 2020 | 5/6/2020 | Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment | Safety and Efficacy of Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment: A Prospective Phase II Trial | Acquired Pure Red Cell Aplasia | Drug: bortezomib/dexamethasone | Institute of Hematology & Blood Diseases Hospital | NULL | Recruiting | 18 Years | 70 Years | All | 17 | Phase 2 | China |